Future perspectives of chemotherapy for advanced gastric cancer

被引:1
作者
Ohtsu, Atsushi [1 ]
Fuse, Nozomu [1 ]
Yoshino, Takayuki [1 ]
Tahara, Makoto [1 ]
Doi, Toshihiko [1 ]
机构
[1] Natl Canc Ctr Hosp E, Div Gastrointestinal Oncol Digest Endoscopy, Kashiwa, Chiba 2778577, Japan
关键词
Gastric cancer; Chemotherapy; Molecular targeting agent; S-1 PLUS CISPLATIN; GROWTH-FACTOR RECEPTOR; RANDOMIZED PHASE-III; GASTROESOPHAGEAL JUNCTION; PROGNOSTIC-SIGNIFICANCE; GENE AMPLIFICATION; TRIAL; FLUOROURACIL; COMBINATION; VEGF;
D O I
10.1007/s10120-008-0461-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
According to the results of two recent randomized studies of treatment for metastatic gastric cancer in Japan, S-1 could replace infusional 5-fluorouracil and S-1 plus cisplatin showed a significant survival advantage over S-1 monotherapy, with a favorable toxicity profile. However, no globally accepted standards have been established yet and we have to wait for the results of other ongoing international studies, including studies of S-1 and its combinations, to achieve such standards. There are two major approaches to achieve further progress in the treatment of advanced gastric cancer. The first is to optimize the use of conventional cytotoxic agents (regimens) in the continuum of treatment for this disease. Several randomized studies of such regimens as second-line treatments are being planned in Japan, for which definitions of eligibility criteria and primary endpoints should be fully discussed in the design of the protocols. The second approach is to incorporate new active agents, particularly molecular targeting agents. Several molecular targeting agents that have shown survival advantages in patients with other tumor types are now under investigation for the treatment of gastric cancer in international randomized studies, including Japan and Korea. The next generation of targeting agents is also being evaluated in early clinical studies. Biological research has become essential for developing new targeting agents. For such biological studies, the tumor tissues of gastric cancer are easily obtainable via endoscopy, and such studies may constitute new frontiers in biological therapy. We expect that these studies will provide not only further clinical advantages but that they will also lead to tailored medicine.
引用
收藏
页码:60 / 66
页数:7
相关论文
共 30 条
  • [1] Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma
    Ajani, JA
    Faust, J
    Ikeda, K
    Yao, JC
    Anbe, H
    Carr, KL
    Houghton, M
    Urrea, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 6957 - 6965
  • [2] Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
    Ajani, JA
    Lec, FC
    Singh, DA
    Haller, DG
    Lenz, HJ
    Benson, AB
    Yanagilhara, R
    Phan, AT
    Yao, JC
    Strumberg, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (04) : 663 - 667
  • [3] [Anonymous], P AM SOC CLIN ONCOL
  • [4] The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer:: Results of a phase I study with pharmacokinetics
    Awada, Ahmad
    Cardoso, Fatima
    Fontaine, Christel
    Dirix, Luc
    De Greve, Jacques
    Sotiriou, Christos
    Steinseifer, Jutta
    Wouters, Carine
    Tanaka, Chiaki
    Zoellner, Ulrike
    Tang, Pui
    Piccart, Martine
    [J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 84 - 91
  • [5] Bang Y, 2007, J CLIN ONCOL, V25
  • [6] Boku N, 2007, J CLIN ONCOL, V25
  • [7] CUNNINGHAM D, 2006, J CLIN ONCOL, V24, P4092
  • [8] Dank M, 2005, J CLIN ONCOL, V23, p308S
  • [9] DOI T, 2005, J CLIN ONCOL, V23, P3077
  • [10] Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
    Dragovich, Tomislav
    McCoy, Sheryl
    Fenoglio-Preiser, Cecilia M.
    Wang, Jiang
    Benedetti, Jacqueline K.
    Baker, Amanda F.
    Hackett, Christopher B.
    Urba, Susan G.
    Zaner, Ken S.
    Blanke, Charles D.
    Abbruzzese, James L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4922 - 4927